Vedolizumab Beats Infliximab as Second-Line UC Therapy ...Middle East

Medscape - News
Vedolizumab Beats Infliximab as Second-Line UC Therapy
In patients with ulcerative colitis, vedolizumab outperformed infliximab as a second-line therapy following failure of anti-TNF therapy. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( Vedolizumab Beats Infliximab as Second-Line UC Therapy )

Also on site :



Latest News